Neratinib/trastuzumab is clinically active in patients with heavily pre-treated, metastatic, HER2-mutated breast cancer.
Physician's Weekly,
Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast cancer and patients with…